CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY

QR Code

CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY

.

Enregistré dans:

Détails bibliographiques
Auteur principal:	A. Budkowska
Format:	article
Langue:	RU
Publié:	Sankt-Peterburg : NIIÈM imeni Pastera 2018
Sujets:	Infectious and parasitic diseases RC109-216
Accès en ligne:	https://doaj.org/article/1d3c81e9d5f844aa8d77430c2378cbda
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

DEVELOPMENT AND APPROBATION METHOD OF IDENTIFICATION MUTATIONS THE RESISTANCE OF THE HEPATITIS C VIRUS TO DIRECT-ACTING ANTIVIRAL AGENTS (DAAs)
par: D. E. Valutite, et autres
Publié: (2018)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
par: Ibrahim Anam Ezzelregal, et autres
Publié: (2020)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
par: Lim TR
Publié: (2014)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
par: Irina RUSU, et autres
Publié: (2020)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
par: Monica Basso, et autres
Publié: (2021)

‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant
par: Fabrizio Fabrizi, et autres
Publié: (2021)

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy
par: Cesare Mazzaro, et autres
Publié: (2021)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
par: Stefania Farcomeni, et autres
Publié: (2021)

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
par: Fei Xiao, et autres
Publié: (2014)

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
par: V. Stalin Raj, et autres
Publié: (2017)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
par: Kamal SM
Publié: (2014)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
par: Atsushi Hosui, et autres
Publié: (2021)

Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis
par: Rosanna Villani, et autres
Publié: (2021)

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
par: María E. Cárdaba-García, et autres
Publié: (2021)

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
par: Abdulla M, et autres
Publié: (2019)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
par: Mercedes Márquez-Coello, et autres
Publié: (2021)

Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.
par: Patrick Maillard, et autres
Publié: (2011)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
par: Kao-Chi Chang, et autres
Publié: (2021)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
par: Tag-Adeen M, et autres
Publié: (2017)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
par: Meritxell Llorens-Revull, et autres
Publié: (2021)

Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome
par: Omar A. Saldarriaga, et autres
Publié: (2021)

Assessment of Left Ventricular Systolic Function by Speckle Tracking in Diabetic Patients Receiving Direct Acting Antiviral Drugs for Chronic HCV
par: Wael Hassib, et autres
Publié: (2021)

HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization
par: Daniel Valle-Millares, et autres
Publié: (2022)

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
par: Yoshimasa Tokuchi, et autres
Publié: (2021)

Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes.
par: Matthew A Burchill, et autres
Publié: (2021)

Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity
par: Tarek Yosef, et autres
Publié: (2021)

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.
par: Bambang S Adiwijaya, et autres
Publié: (2012)

How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
par: DING Yang
Publié: (2021)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
par: Vicente Soriano, et autres
Publié: (2022)

L3 Skeletal Muscle Index Dynamics in Patients with HCV-Related Compensated Cirrhosis Following Sustained Virological Response after Direct Acting Antiviral Treatment
par: Florin Mihai, et autres
Publié: (2021)

Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
par: Heng Lee, et autres
Publié: (2021)

Effects of Hepatitis C Virus Elimination by Direct-Acting Antiviral Agents on the Occurrence of Oral Lichen Planus and Periodontal Pathogen Load: A Preliminary Report
par: Yumiko Nagao, et autres
Publié: (2021)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
par: Naoki Kawagishi, et autres
Publié: (2021)

Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
par: Hung-Yin Liu, et autres
Publié: (2021)

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan
par: Chun-Ming Hong, et autres
Publié: (2021)

The role of PTEN - HCV core interaction in hepatitis C virus replication
par: Qi Wu, et autres
Publié: (2017)

Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.
par: Stéphane Chevaliez, et autres
Publié: (2009)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
par: Arif Qayyum Khan, et autres
Publié: (2020)

Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
par: Elabd NS, et autres
Publié: (2021)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
par: Arif Qayyum Khan, et autres
Publié: (2020)